2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Recurrence
3
Neoplasms
3
Glioma
3
Triple Negative Breast Neoplasms
2
Sarcoma
2
Multiple Myeloma
2
Lymphoma, Non-Hodgkin
2
Lymphoma
2
Wilms Tumor
1
Waldenstrom Macroglobulinemia
1
Sarcoma, Synovial
1
Sarcoma, Ewing
1
Rhabdomyosarcoma
1
Rhabdoid Tumor
1
Prostatic Neoplasms
1
Paraproteinemias
1
Ovarian Neoplasms
1
Osteosarcoma
1
Neuroectodermal Tumors, Primitive
1
Neuroblastoma
1
Neoplasms, Plasma Cell
1
Neoplasms, Neuroepithelial
1
Medulloblastoma
1
Lymphoproliferative Disorders
1
Lymphoma, Mantle-Cell
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma, B-Cell, Marginal Zone
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Immunoproliferative Disorders
1
Hodgkin Disease
1
Interventions
Rituximab
161
Cyclophosphamide
142
fludarabine phosphate
89
Peripheral Blood Stem Cell Transplantation
81
Filgrastim
59
Mycophenolic Acid
58
Whole-Body Irradiation
53
Cyclosporine
53
Radiotherapy
52
Lenalidomide
47
Busulfan
45
Tacrolimus
44
Etoposide
43
Antilymphocyte Serum
41
Melphalan
37
Methotrexate
31
fludarabine
30
Bortezomib
30
Prednisone
28
Bendamustine Hydrochloride
28
Cytarabine
24
Cord Blood Stem Cell Transplantation
23
obinutuzumab
22
Vincristine
22
Methylprednisolone
21
Flow Cytometry
21
ibrutinib
19
venetoclax
18
sargramostim
17
Granulocyte Colony-Stimulating Factor
17
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Lymphoma, B-Cell, Marginal Zone
×
CLR1404
×
Clear all
NCT02952508
2026-03-18
CLOVER-WaM
Cellectar Biosciences, Inc.
Phase 2
Active not recruiting
120 enrolled